Clinical Trials Browser

Phase 1 × Melanoma × Protein Subunit Vaccines × Clear all

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

Melanoma

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1 Completed

Melanoma

NCT00471471 2017-06-22

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 1 Completed

Uveal Melanoma, Melanoma